Usage of Baclofen for Sleep Improvement After Cardiac Surgery

NCT ID: NCT02529514

Last Updated: 2016-05-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

SUSPENDED

Clinical Phase

PHASE4

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-07-31

Study Completion Date

2016-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Baclo-Sleep trial aims to investigate the effect of baclofen on sleep after scheduled cardiac surgery.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a prospective randomized single-blind study involving patients adults admitted to the University Hospital of Liege for a scheduled heart surgery.

The study is based on the oral administration of baclofen (or placebo) the evening Bedrooms (10 pm). This administration begins the day before surgery and ends 5th day after. Sleep is evaluated by various questionnaires at baseline, during the protocol and the end. In addition, a 24 polysomnography is performed the day after surgery.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sleep

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Baclofen

Baclofen 25 mg per os for 7 days at 10 pm every day

Group Type ACTIVE_COMPARATOR

Baclofen

Intervention Type DRUG

25 mg for 7 days at 10 pm every day

Placebo

Placebo per os for 7 days at 10 pm every day

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo for 7 days at 10 pm every day

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Baclofen

25 mg for 7 days at 10 pm every day

Intervention Type DRUG

Placebo

Placebo for 7 days at 10 pm every day

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Elective cardiac surgery

Exclusion Criteria

* Haemodynamic instability
* Epilepsy
* Psychotic disturbances
* Acute / Chronic respiratory failure
* Morbid obesity (BMI \> 45 kg/m2)
* Sleep apnea (treated)
* Severe hepatic or renal failure
* Patient refusal
Minimum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Liege

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Damien Wertz

MD

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pierre Damas, Professor

Role: STUDY_DIRECTOR

Soins intensifs généraux

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centre Hospitalier Universitaire de Liège

Liège, Liège, Belgium

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Baclo-Sleep

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Oral Bedtime Melatonin in Critically Ill Patients
NCT06156059 NOT_YET_RECRUITING PHASE4
Improving Sleep Quality in Heart Failure
NCT03307005 COMPLETED PHASE4
Insomnia and Drug Relapse Risk
NCT00253890 COMPLETED PHASE3